Full Press Release Details
Affimed Announces Annual General Meeting
Heidelberg, Germany, May 23, 2016 -
Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer
immunotherapies, announced today that the Annual General Meeting of Shareholders will be held on Tuesday, June 21, 2016. The meeting
will be held at Hilton Amsterdam, Apollolaan 138, 1077 BG Amsterdam, The Netherlands. The meeting will start at 3:00 p.m. CET.
The notice and agenda of the general meeting
are available free of charge in the Investor Relations section under "Notice to convene the Annual General Meeting of Shareholders
of Affimed N.V." of Affimed's corporate website at www.affimed.com. They are also available on the SEC's website at www.sec.gov.
Affimed (Nasdaq: AFMD) engineers targeted
immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing
single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: IR@affimed.com or c.stewart@affimed.com
Anca Alexandru, Head of Communications
Phone: +49 6221 64793341
E-Mail: a.alexandru@affimed.com